| Literature DB >> 34068126 |
Monika Czech1, Maria Konopacka2, Jacek Rogoliński2, Zbigniew Maniakowski3, Magdalena Staniszewska4,5, Łukasz Łaczmański5, Danuta Witkowska5, Andrzej Gamian5,6.
Abstract
An association between the cancer invasive activities of cells and their exposure to advanced glycation end-products (AGEs) was described early in some reports. An incubation of cells with BSA-AGE (bovine serum albumin-AGE), BSA-carboxymethyllysine and BSA-methylglyoxal (BSA-MG) resulted in a significant increase in DNA damage. We examined the genotoxic activity of new products synthesized under nonaqueous conditions. These were high molecular mass MAGEs (HMW-MAGEs) formed from protein and melibiose and low molecular mass MAGEs (LMW-MAGEs) obtained from the melibiose and N-α-acetyllysine and N-α-acetylarginine. We have observed by measuring of micronuclei in human lymphocytes in vitro that the studied HMW-MAGEs expressed the genotoxicity. The number of micronuclei (MN) in lymphocytes reached 40.22 ± 5.34 promille (MN/1000CBL), compared to 28.80 ± 6.50 MN/1000 CBL for the reference BSA-MG, whereas a control value was 20.66 ± 1.39 MN/1000CBL. However, the LMW-MAGE fractions did not induce micronuclei formation in the culture of lymphocytes and partially protected DNA against damage in the cells irradiated with X-ray. Human melanoma and all other studied cells, such as bronchial epithelial cells, lung cancer cells and colorectal cancer cells, are susceptible to the genotoxic effects of HMW-MAGEs. The LMW-MAGEs are not genotoxic, while they inhibit HMW-MAGE genotoxic activity. With regard to apoptosis, it is induced with the HMW-MAGE compounds, in the p53 independent way, whereas the low molecular mass product inhibits the apoptosis induction. Further investigations will potentially indicate beneficial apoptotic effect on cancer cells.Entities:
Keywords: MAGEs; advanced glycation; advanced glycation end-products; apoptosis; genotoxicity; glycation products; micronuclei assay
Year: 2021 PMID: 34068126 PMCID: PMC8152725 DOI: 10.3390/genes12050729
Source DB: PubMed Journal: Genes (Basel) ISSN: 2073-4425 Impact factor: 4.096
Figure 1Chromatography on HW40S column in 0.1 M ammonium acetate of the LMW products formed from D-melibiose in reaction with N-α-acetyl-L-lysine, resulting in several fractions (upper panel), and the obtained fractions from the LM3 desalted on a Bio-Gel P-2 column (lower panel).
Figure 2The impact of HMW–MAGE derived from BSA and D-melibiose or methylglyoxal on DNA damage in human PBL (A) and genotoxic activity of LMW–MAGE synthesized in reaction of D-melibiose, N-α-acetyl-L-lysine and N-α-acetyl-L-arginine (LMA) or from a mixture of D-melibiose and N-α-acetyl-L-lysine (LM) (B); * indicates p < 0.05.
Micronuclei analysis results of advanced glycation end-products genotoxicity, obtained in two sets of experiments.
| Tested Compounds | Concentration | Frequencies of MN/1000 CBL | Fraction of | t-Welch | |||
|---|---|---|---|---|---|---|---|
| Negative control | - | 20.66 ± 1.39 | - | - | 19.3 ± 1.84 | - | - |
| BSA monomer | 100 | 18.00 ± 1.61 | −27.964 | <0.005 | 16.3 ± 1.52 | −28.107 | <0.005 |
| Melibiose | 100 | 18.61 ± 1.69 | −20.948 | <0.005 | 17.8 ± 1.24 | −15.117 | <0.005 |
| BSA–mel fr. II HTG | 100 | 40.22 ± 5.34 | 79.264 | <0.005 | 38.0 ± 5.12 | 76.857 | <0.005 |
| BSA–mel fr. II HTG | 50 | 25.70 ± 1.87 | 48.368 | <0.005 | 24.6 ± 2.82 | 35.196 | <0.005 |
| BSA–MG | 100 | 28.80 ± 6.50 | 27.383 | <0.005 | 29.3 ± 4.09 | 49.858 | <0.005 |
| BSA–MG | 50 | 24.89 ± 5.26 | 17.385 | <0.005 | 21.5 ± 2.88 | 14.394 | <0.005 |
| LM 3C | 100 | 17.30 ± 1.25 | −40.191 | <0.005 | 17.0 ± 1.01 | −24.502 | <0.005 |
| LMA 5A | 100 | 19.20 ± 1.63 | −15.240 | <0.005 | 17.4 ± 1.66 | −17.144 | <0.005 |
| Negative control | - | 29.25 ± 2.77 | - | - | 27.00 ± 0.71 | ||
| Bleomycin | 10 | 105.50 ± 7.76 | 206.93 | <0.005 | 82.50 ± 5.22 | 235.57 | <0.005 |
| 100 | 30.20 ± 2.99 | 5.21 | <0.005 | 26.20 ± 1.47 | −10.95 | <0.005 | |
| 100 | 28.46 ± 2.21 | −4.98 | <0.005 | 26.00 ± 1.51 | −13.40 | <0.005 | |
| Melibiose | 100 | 27.75 ± 1.92 | −9.95 | <0.005 | 26.40 ± 2.01 | −6.29 | <0.005 |
| LMA 5A | 10 | 26.33 ± 0.94 | −22.32 | <0.005 | 24.67 ± 1.89 | −25.80 | <0.005 |
| 50 | 27.50 ± 2.06 | −11.33 | <0.005 | 25.75 ± 2.86 | −9.48 | <0.005 | |
| 100 | 30.25 ± 1.79 | 6.78 | <0.005 | 28.25 ± 2.05 | 12.88 | <0.005 | |
| LMA 5B | 10 | 30.33 ± 4.03 | 4.93 | <0.005 | 28.30 ± 2.62 | 10.71 | <0.005 |
| 50 | 29.00 ± 2.16 | −1.59 | 0.1118 | 25.33 ± 1.25 | −25.98 | <0.005 | |
| 100 | 27.50 ± 1.66 | −12.11 | <0.005 | 25.00 ± 1.87 | −22.36 | <0.005 |
BSA–mel fr. II HTG and BSA–MG: fractions of HMW–MAGE obtained after BSA glycation with D-melibiose or methylglyoxal, respectively; LM 3C, LMA 5A and LMA 5B: fractions of LMW–MAGE obtained after HW40S gel filtration of products from D-melibiose reaction with N-α-acetyl-L-lysine (LM 3C) or reaction products of D-melibiose with N-α-acetyl-L-lysine and N-α-acetyl-L-arginine (LMA 5A, LMA 5B); MN/1000 CBL: micronuclei occurring in binucleated lymphocytes; Negative control: culturing medium.
Damage of human PBLs DNA in the presence of equivalent concentrations of HMW– and LMW–MAGE in the cell culture.
| Tested Compound | Concentration | Frequency of | Fraction of | ||||
|---|---|---|---|---|---|---|---|
| Negative control | - | 23.30 ± 1.24 | - | - | 21.60 ± 0.94 | - | - |
| BSA–mel-II | 100 | 41.33 ± 2.86 | 129.33 | <0.005 | 36.00 ± 2.94 | 104.32 | <0.005 |
| BSA–mel-II + LM 3C | 100 | 42.66 ± 4.49 | 92.94 | <0.005 | 36.10 ± 3.29 | 94.76 | <0.005 |
| BSA–mel-II + LMA 5A | 100 | 42.00 ± 2.94 | 131.05 | <0.005 | 36.33 ± 2.05 | 146.05 | <0.005 |
| BSA MG | 100 | 32.33 ± 1.69 | 96.33 | <0.005 | 29.66 ± 1.24 | 115.83 | <0.005 |
| BSA–MG + LM 3C | 100 | 33.70 ± 1.69 | 110.94 | <0.005 | 30.00 ± 1.41 | 110.84 | <0.005 |
| BSA–MG + LM 2D/2 | 100 | 33.86 ± 2.04 | 98.91 | <0.005 | 30.10 ± 0.82 | 152.37 | <0.005 |
BSA–mel-II and BSA–MG: fractions of HMW–MAGE obtained after BSA glycation with D-melibiose or methylglyoxal, respectively; LM 3C and LMA 2D/2: fractions of LMW–MAGE obtained after HW40S gel filtration of products from D-melibiose reaction with only N-α-acetyl-L-lysine (LM 3C) or product reaction of D-melibiose with N-α-acetyl-L-lysine and N-α-acetyl-L-arginine (LMA 2D/2); Negative control: culturing medium.
Effect of advanced glycation end-products on the formation of micronuclei induced by X-radiation in human lymphocytes in vitro.
| Tested Compounds | Concentration (μg/mL) | Frequency of | Fraction of | ||||
|---|---|---|---|---|---|---|---|
| Negative control | - | 28.35 ± 3.49 | - | - | 25.50 ± 2.04 | - | - |
| X-rays (2 Gy) | - | 322.50 ± 21.61 | 300.47 | <0.005 | 287.25 ± 25.58 | 228.08 | <0.005 |
| LMA 5A + irradiation | 1 | 310.17 ± 12.01 | 503.86 | <0.005 | 268.05 ± 30.26 | 178.83 | <0.005 |
| 10 | 297.72 ± 10.11 | 563.16 | <0.005 | 241.00 ± 15.05 | 317.28 | <0.005 | |
| 100 | 289.25 ± 13.63 | 414.64 | <0.005 | 237.50 ± 12.22 | 382.63 | <0.005 | |
| LMA 5B + irradiation | 1 | 341.00 ± 11.37 | 587.8 | <0.005 | 277.60 ± 12.04 | 461.62 | <0.005 |
| 10 | 298.00 ± 14.9 | 394 | <0.005 | 244.36 ± 8.50 | 559.85 | <0.005 | |
| 100 | 297.75 ± 10.22 | 557.8 | <0.005 | 245.50 ± 8.77 | 546.34 | <0.005 | |
| 1 | 313.00 ± 21.33 | 294.49 | <0.005 | 252.10 ± 15.51 | 323.9 | <0.005 | |
| 10 | 337.44 ± 20.42 | 333.63 | <0.005 | 266.00 ± 20.61 | 259.66 | <0.005 | |
| 100 | 310.33 ± 7.89 | 730.84 | <0.005 | 251.00 ± 8.48 | 578.12 | <0.005 | |
| Melibiose + irradiation | 1 | 319.00 ± 10.71 | 576.97 | <0.005 | 249.67 ± 8.34 | 583.82 | <0.005 |
| 10 | 340.62 ± 10.66 | 622.51 | <0.005 | 264.50 ± 11.94 | 441.19 | <0.005 | |
| 100 | 298.30 ± 22.66 | 263.28 | <0.005 | 240.67 ± 14.29 | 333.31 | <0.005 | |
| 1 | 332.00 ± 16.39 | 405.18 | <0.005 | 261.10 ± 13.34 | 390.38 | <0.005 | |
| 10 | 330.00 ± 19.03 | 348.63 | <0.005 | 266.67 ± 15.82 | 338.08 | <0.005 | |
| 100 | 341.65 ± 17.40 | 394.76 | <0.005 | 262.00 ± 21.18 | 248.53 | <0.005 |
Abbreviations: see Table 1.
The effect of advanced glycation end-products on BEAS-2B cells.
| Tested Compounds | Concentration | Cells with Micronuclei (%) | Number of Micronuclei in 100 Cells | Cell Division Index NDI (%) | Apoptotic Cells |
|---|---|---|---|---|---|
| Negative control | - | 2.9 | 2.9 | 2.1 | 3.3 |
| MB–mel | 1 | 2.9 | 2.9 | 2.09 | 3.2 |
| 10 | 2.9 | 2.9 | 2.01 | 3.5 | |
| 20 | 2.8 | 2.8 | 2.07 | 3.5 | |
| 50 | 2.8 | 2.9 | 1.99 | 3.6 | |
| 100 | 3.3 | 4.1 | 2.01 | 3.5 | |
| MB–mel | 1 | 3.4 | 3.4 | 2.04 | 3.5 |
| 10 | 4 | 4.2 | 1.95 | 3.8 | |
| 20 | 5.1 | 5.7 | 2.02 | 3.9 | |
| 50 | 5.7 | 6 | 2.09 | 4 | |
| 100 | 5.7 | 6.5 | 1.99 | 3.9 | |
| Melibiose | 100 | 2.8 | 2.9 | 2.1 | 3.4 |
| Myoglobin | 100 | 2.9 | 2.9 | 2.02 | 3 |
| Bleomycin | 10 | 13.5 | 19.5 | 1.33 | 5 |
The effect of advanced glycation end-products on A549 cells.
| Tested Compounds | Concentration | Cells with Micronuclei (%) | Number of Micronuclei in 100 Cells | Cell Division Index NDI (%) | Apoptotic Cells |
|---|---|---|---|---|---|
| Negative control | - | 2.2 | 2.1 | 2.09 | 1.1 |
| MB–mel | 1 | 2.1 | 2.1 | 2.00 | 1.1 |
| 10 | 2.2 | 1.6 | 1.99 | 1.2 | |
| 20 | 2.1 | 2.2 | 1.98 | 1.2 | |
| 50 | 2.2 | 2.4 | 2.04 | 1.2 | |
| 100 | 2.1 | 2.3 | 2.00 | 1.2 | |
| MB–mel | 1 | 2.3 | 2.7 | 2.00 | 1.4 |
| 10 | 2.8 | 3.3 | 1.96 | 1.7 | |
| 20 | 3.0 | 3.6 | 2.03 | 1.6 | |
| 50 | 3.1 | 3.8 | 1.96 | 1.7 | |
| 100 | 3.3 | 4.3 | 1.95 | 2.4 | |
| Melibiose | 100 | 2.1 | 2.1 | 2.05 | 1.1 |
| Myoglobin | 100 | 2.1 | 2.2 | 2.08 | 1.2 |
| Bleomycin | 10 | 15.9 | 24.4 | 1.56 | 2.7 |
The effect of advanced glycation end-products on HCT 116 (-/-) cells.
| Tested Compounds | Concentration | Cells with Micronuclei (%) | Number of Micronuclei in 100 Cells | Cell Division Index NDI (%) | Apoptotic |
|---|---|---|---|---|---|
| Negative control | 0 | 1.5 | 1.2 | 1.94 | 1.3 |
| MB–mel | 1 | 1.6 | 1.6 | 1.99 | 1.4 |
| 10 | 1.5 | 1.6 | 1.99 | 1.3 | |
| 20 | 1.5 | 1.6 | 1.93 | 1.4 | |
| 50 | 1.5 | 1.6 | 2.01 | 1.3 | |
| 100 | 1.7 | 1.8 | 2.01 | 1.5 | |
| MB–mel | 1 | 1.8 | 1.8 | 1.99 | 1.3 |
| 10 | 3.5 | 3.8 | 1.98 | 1.3 | |
| 20 | 4.4 | 5.3 | 1.92 | 1.5 | |
| 50 | 4.9 | 5.2 | 1.95 | 1.4 | |
| 100 | 6.2 | 6.8 | 1.94 | 1.6 | |
| Melibiose | 100 | 1.5 | 1.5 | 2.01 | 1.3 |
| Myoglobin | 100 | 1.4 | 1.1 | 1.98 | 1.3 |
| Bleomycin | 10 | 11.6 | 15.2 | 1.37 | 2.3 |
The effect of advanced glycation end-products on SK-MEL cells.
| Concentration (μg/mL) | Cells with Micronuclei (%) | Cell Division Index NDI (%) | Apoptotic Cells (%) | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| MB–mel | LM 3C | |||||||||
| 0 | 0 | 1 | 2 | 1 | 1.92 | 1.97 | 1.84 | 0.8 | 0.6 | 0.5 |
| 10 | 0 | 2 | 2 | 1 | 2.04 | 1.95 | 1.92 | 0.7 | 0.5 | 0.8 |
| 20 | 0 | 4 | 4 | 5 | 1.92 | 1.94 | 1.86 | 0.9 | 1.2 | 0.9 |
| 50 | 0 | 5 | 4 | 6 | 2 | 1.92 | 1.94 | 1.5 | 1.7 | 1.4 |
| 0 | 10 | 1 | 1 | 2 | 1.96 | 2.08 | 2.05 | 0.5 | 0.5 | 0.7 |
| 0 | 20 | 2 | 1 | 1 | 2.08 | 1.9 | 1.92 | 0.4 | 0.6 | 0.6 |
| 0 | 50 | 1 | 2 | 2 | 1.95 | 1.92 | 1.98 | 0.6 | 0.5 | 0.8 |
| 10 | 10 | 2 | 1 | 1 | 1.87 | 1.95 | 1.94 | 0.5 | 0.7 | 0.7 |
| 20 | 20 | 3 | 2 | 2 | 1.98 | 2.1 | 1.95 | 0.6 | 0.6 | 0.7 |
| 50 | 50 | 3 | 3 | 2 | 2.04 | 1.96 | 1.94 | 0.5 | 0.7 | 0.5 |
| Bleomycin 10 μg/ml | 18 | 21 | 17 | 1.47 | 1.68 | 1.52 | 2.8 | 3 | 2.4 | |
The effect of LMW–MAGE on genotoxic activity of HTG glycation products in BEAS-2B cells.
| Concentration | Cells with | Number of | Apoptotic Cells (%) | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Negative control | - | 3.1 | 2.6 | 2.8 | 3.1 | 2.6 | 2.8 | 3.0 | 3.2 | 3.2 |
| MB–mel HTG | 20 | 6.0 | 5.2 | 5.7 | 6.4 | 5.5 | 6.1 | 3.8 | 4.1 | 3.6 |
| MB–mel HTG | 20 | 5.0 | 6.1 | 5.5 | 5.6 | 6.3 | 5.7 | 3.5 | 3.9 | 3.3 |
| MB–mel HTG | 20 | 4.0 | 4.8 | 4.4 | 4.2 | 4.8 | 4.8 | 3.1 | 3.3 | 3.3 |
| MB–mel HTG | 20 | 4.2 | 4.6 | 4.7 | 4.2 | 4.8 | 4.9 | 3.5 | 3.2 | 3.4 |
| Melibiose | 100 | 2.7 | 3.1 | 3.0 | 2.7 | 3.1 | 3.0 | 3.2 | 3.0 | 3.0 |
| Myoglobin | 100 | 2.6 | 2.8 | 3.1 | 2.6 | 2.8 | 3.1 | 3.0 | 3.2 | 2.9 |
| LM 3A | 10 | 3.0 | 3.0 | 2.9 | ||||||
| LM 3B | 10 | 2.8 | 2.8 | 3.1 | ||||||
| LM 3C | 10 | 3.0 | 3.0 | 2.9 | ||||||
The effect of LMW–MAGE on genotoxic activity of HTG glycation products in A549 cells.
| Concentration | Cells with | Number of | Apoptotic Cells (%) | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Control | 0 | 2.0 | 1.9 | 2.2 | 2.0 | 1.9 | 2.2 | 1.0 | 1.2 | 1.0 |
| MB–mel HTG | 20 | 3.4 | 3.8 | 3.3 | 3.6 | 4.1 | 3.5 | 1.4 | 1.8 | 2.0 |
| MB–mel HTG | 20 | 3.6 | 3.4 | 3.2 | 3.6 | 3.6 | 3.4 | 1.5 | 1.7 | 2.9 |
| MB–mel HTG | 20 | 2.6 | 2.8 | 3.0 | 2.6 | 3.0 | 3.4 | 1.1 | 1.3 | 1.1 |
| MB–mel HTG | 20 | 2.7 | 3.1 | 3.0 | 2.7 | 3.3 | 3.0 | 1.2 | 1.0 | 1.3 |
| Melibiose | 100 | 1.8 | 2.0 | 2.0 | 1.8 | 2.0 | 2.0 | 1.1 | 0.9 | 1.0 |
| Myoglobin | 100 | 2.0 | 2.2 | 2.0 | 2.0 | 2.2 | 2.0 | 1.0 | 1.0 | 1.2 |
| LM 3A | 10 | 1.9 | 1.9 | 0.9 | ||||||
| LM 3B | 10 | 2.2 | 2.2 | 1.1 | ||||||
| LM 3C | 10 | 2.0 | 2.0 | 1.0 | ||||||
The effect of LMW–MAGE on genotoxic activity of HTG glycation products in HCT 116 (-/-) cells.
| Concentration | Cells with | Number of | Apoptotic Cells (%) | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Negative control | 0 | 1.3 | 1.4 | 1.8 | 1.3 | 1.4 | 1.8 | 1.5 | 1.1 | 1.2 |
| MB–mel HTG | 20 | 4.5 | 4.2 | 4.8 | 5.5 | 5.2 | 5.8 | 1.5 | 1.8 | 1.6 |
| MB–mel HTG | 20 | 4.6 | 4.0 | 4.4 | 5.2 | 4.4 | 4.6 | 1.5 | 1.3 | 1.6 |
| MB–mel HTG | 20 | 3.8 | 3.6 | 3.5 | 4.0 | 4.2 | 3.8 | 1.4 | 1.1 | 1.4 |
| MB–mel HTG | 20 | 3.9 | 3.7 | 4.2 | 4.5 | 4.4 | 4.2 | 1.2 | 1.6 | 1.5 |
| Melibiose | 100 | 1.3 | 1.7 | 1.5 | 1.3 | 1.7 | 1.5 | 1.5 | 1.1 | 1.4 |
| Myoglobin | 100 | 1.6 | 1.6 | 1.8 | 1.6 | 1.6 | 1.8 | 1.0 | 1.4 | 1.2 |
| LM 3A | 10 | 1.4 | 1.4 | 1.2 | ||||||
| LM 3B | 10 | 1.7 | 1.7 | 1.0 | ||||||
| LM 3C | 10 | 1.4 | 1.5 | 1.4 | ||||||